Table 2.
Clinical characteristics of patients with FFPE tissue samples.
| Total | DOCETAXEL | CABAZITAXEL | P-value | |
|---|---|---|---|---|
| Patients, N (%) | 117* | 103 (72)* | 40 (28)* | |
| (*26 (22.2) received both D and CZ) | (*77 (65.8) received only D) | (*14 (12) received only CZ) | ||
| Age* (years) | ||||
| Median (range) | 69.5 (41.6 - 87.1) | 69.4 (41.6 - 87.1) | 68.7 (43.2 - 83.3) | |
| Tumour origin, N (%) | ||||
| Primary | 104 (88.9) | 92 (89.3) | 37 (92.5) | 0.757 |
| Metastatic | 13 (11.1) | 11 (10.7) | 3 (7.5) | |
| Tumour Hormonal Status, N (%) | ||||
| HS | 93 (79.5) | 81 (78.6) | 34 (85) | 0.485 |
| CRPC | 24 (20.5) | 22 (21.4) | 6 (15) | |
| Stage at diagnosis, N (%) | ||||
| <IV | 36 (30.8) | 33 (32) | 12 (30) | 0.430 |
| IV | 65 (55.6) | 54 (52.4) | 28 (70) | |
| NA | 16 (13.7) | 16 (15.5) | 0 (0) | |
| Gleason sum at diagnosis, N (%) | ||||
| ≤7 | 37 (31.6) | 34 (33) | 8 (20) | 0.148 |
| ≥8 | 73 (62.4) | 63 (61.2) | 30 (75) | |
| NA | 7 (6) | 6 (5.8) | 2 (5) | |
| Best PSA response, N (%) | ||||
| Stable disease | 39 (33.3) | 31 (30.1) | 19 (47.5) | |
| Partial response | 58 (49.6) | 56 (54.4) | 9 (22.5) | |
| Progression | 18 (15.4) | 15 (14.6) | 11 (27.5) | |
| NA | 2 (1.7) | 1 (1) | 1 (2.5) | |
| Metastases at diagnosis, N (%) | ||||
| Yes | 54 (46.2) | 44 (42.7) | 23 (57.5) | 0.564 |
| No | 43 (36.8) | 39 (37.9) | 16 (40) | |
| NA | 20 (17.1) | 20 (19.4) | 1 (2.5) | |
| Presence of bone metastases, N (%) | ||||
| Yes | 99 (84.6) | 86 (83.5) | 35 (87.5) | 1 |
| No | 9 (7.7) | 8 (7.8) | 3 (7.5) | |
| NA | 9 (7.7) | 9 (8.7) | 2 (5) | |
| Presence of visceral metastases*, N (%) | ||||
| Yes | 39 (33.3) | 31 (30.1) | 16 (40) | 0.325 |
| No | 69 (59) | 63 (61.2) | 22 (55) | |
| NA | 9 (7.7) | 9 (8.7) | 2 (5) | |
| ECOG performance status score*, N (%) | ||||
| 0 | 17 (14.5) | 16 (15.5) | 2 (5) | 0.092 |
| 1 or 2 | 84 (71.8) | 72 (69.9) | 35 (87.5) | |
| NA | 16 (13.7) | 15 (14.6) | 3 (7.5) | |
| Baseline PSA (ng/mL) | ||||
| Median (range) | 62.8 (0.04 - 1565) | 62.8 (0.2 - 922.6) | 173.3 (0.04 - 1565) | 0.064 |
| Baseline haemoglobin concentration (g/L) | ||||
| Median (range) | 128 (60 - 166) | 128 (67 - 166) | 117 (60 - 151) | 0.014 |
| Baseline alkaline phosphatase (U/L) | ||||
| Median (range) | 178 (17 - 3160) | 161 (17 - 3160) | 225 (65 - 698) | 0.073 |
| Baseline lactate dehydrogenase (U/L) | ||||
| Median (range) | 366 (153 - 1255) | 369 (153 - 1255) | 436.5 (190 - 1536) | 0.008 |
| A/E treatment pre-taxanes, N (%) | ||||
| Yes | 35 (29.9) | 28 (27.2) | 22 (55) | 0.003 |
| No | 82 (70.1) | 75 (72.8) | 18 (45) |
P-value is based on Fisher exact test and Mann-Whitney U test for categorical and continuous variables, respectively. N, number of cases; *data at taxanes start time; ECOG, Eastern Cooperative Oncology Group; A/E, Abiraterone/Enzalutamide therapy; PSA, prostate-specific antigen; D, Docetaxel; CZ, Cabazitaxel; HS, hormone sensitive; CRPC, castration-resistant prostate cancer; NA, not available.